Why Life-Saving Insulin Costs So Much More in America Than Anywhere Else

Over a century ago, the discovery of insulin was intended to serve as a universal medical utility rather than a corporate asset. The researchers who pioneered the treatment believed that a hormone essential for life should be accessible to everyone who required it to survive. However, in the modern American pharmaceutical market, that original vision of accessibility has been replaced by a complex pricing structure that frequently places the drug out of reach for those without comprehensive insurance coverage.

While insulin costs are beginning to stabilize due to recent federal intervention and manufacturer price cuts, the economic forces that drove the cost of the medication upward for decades remain deeply embedded in the U.S. healthcare system. Today, a patient in the United States often faces a market where prices are significantly decoupled from the actual cost of manufacture. According to a study published in BMJ Global Health, the cost to produce a 10ml vial of human insulin is estimated to range between $2.28 and $3.42. Even analog insulins, which provide more predictable blood sugar control, carry manufacturing costs estimated between $3.94 and $6.34.

The study findings indicate that the retail prices for insulin analogs do not correlate with these production expenses. Instead, prices are influenced by a series of market interventions and supply chain markups that occur between the laboratory and the patient.

Source: BMJ Global Health & Eli Lilly (2018-2023 Data)

For years, the list price for common insulins followed a steep upward trajectory. By 2023, the list price for a vial of Humalog reached approximately $274.70. This divergence is the result of a uniquely American ecosystem of intermediaries and patent strategies that have transformed a century-old medical necessity into a significant revenue driver for a handful of global corporations.

The Middleman’s Cut

On the factory floor, a vial of insulin costs less than a gallon of premium gasoline. By the time it reaches a pharmacy counter, the price has been inflated by a gauntlet of negotiators who never touch the medicine. Pharmacy Benefit Managers (PBMs) serve as the primary architects of this pricing structure. Three dominant firms—CVS Caremark, Express Scripts, and OptumRx—manage approximately 80 percent of all prescriptions in the United States.

PBMs negotiate on behalf of insurance companies and employers, using their market share to secure discounts from drug manufacturers. However, these negotiations are centered on “rebates”—payments made by manufacturers back to the PBM in exchange for a drug receiving “preferred” status on a formulary. Because these rebates are frequently calculated as a percentage of a drug’s list price, the system creates a perverse incentive for PBMs to favor medications with higher sticker prices.

This dynamic has led to a widening “gross-to-net gap.” While the net price—the amount manufacturers actually receive after paying out rebates—has trended downward or remained flat for several products over the last decade, list prices remained high. For patients who are uninsured or have high-deductible health plans, these inflated list prices function as a significant financial barrier to care.

The Federal Trade Commission (FTC) has intensified its scrutiny of these practices, launching investigations into whether PBMs have utilized “rebate walls.” These are arrangements that may intentionally exclude lower-cost generic or biosimilar versions of insulin from insurance coverage, effectively steering patients toward higher-priced brand-name products that offer larger rebates to the PBM.

The Patent Thicket

In a standard competitive market, the presence of high margins and a large patient base would typically attract low-cost competitors. In the U.S. insulin market, however, competitive pressure has been mitigated by the use of “patent thickets.” This strategy involves filing dozens of subsequent patents on a single drug, covering everything from minor chemical variations to the mechanical design of the injector pens used to administer the dose.

According to analysis of pharmaceutical patenting trends, these “evergreening” strategies allow manufacturers to extend their market exclusivity long after the primary patent on the insulin molecule itself has expired. This has historically allowed the “Big Three” manufacturers—Eli Lilly, Novo Nordisk, and Sanofi—to maintain a collective hold on the U.S. market. This concentration of market power, combined with the rebate-driven PBM system, has ensured that even as manufacturing processes became more efficient, consumer costs remained elevated.

A Global Outlier

The price of insulin in the United States is a significant departure from international norms. A study by the RAND Corporation found that U.S. insulin prices across all categories are 9.7 times higher than the average across 33 other OECD countries. While the average price per unit in these peer nations was approximately $6.94, the U.S. remains the only major economy without a centralized mechanism for drug price negotiation.

The RAND research highlights that while the U.S. accounts for only 15 percent of the global insulin market by volume, it generates nearly 50 percent of the global revenue for these medications. This disparity suggests that the American market serves as the primary profit center for global manufacturers, largely because the U.S. healthcare system lacks the unified bargaining power found in nationalized or highly regulated health systems in Europe and elsewhere.

Policy Shifts and Market Response

The landscape of insulin pricing began to transform following the passage of the Inflation Reduction Act (IRA). A central component of this legislation was a $35 monthly cap on out-of-pocket insulin costs for seniors enrolled in Medicare Part D. This cap addressed a decade of explosive growth in Medicare spending on insulin, which rose from $1.4 billion in 2007 to $13.3 billion by 2020.

Following this federal mandate, the private sector began to adjust. In 2023, Eli Lilly announced a 70 percent reduction in the list prices of its most widely used insulins and implemented its own $35-per-month cap for patients with commercial insurance. Novo Nordisk and Sanofi followed with similar price reductions in early 2024. These shifts were driven not only by public pressure but also by “Medicaid rebate” penalties, which require drugmakers to pay rebates to the government if their price increases exceed the rate of inflation.

Despite these lower list prices, the underlying infrastructure of the drug market remains focused on intermediary fees. Manufacturers have noted in public filings and congressional testimony that while list prices have been reduced, the complex network of PBMs and wholesalers still dictates the final cost sharing experienced by the patient.

The Persistence of High Costs

The financial burden of diabetes extends beyond the cost of a single vial. Beyond the insulin itself, patients must manage the costs of continuous glucose monitors, test strips, and the treatment of long-term complications. The systemic impact of high costs is evidenced by data from the Annals of Internal Medicine, which found that 1.3 million Americans—roughly 16.5 percent of those with diabetes—have reported rationing their insulin. This practice of skipping doses or delaying refills is directly linked to severe health outcomes, including kidney failure and vision loss.

By mid-2024, the $35 cap has become a benchmark for the industry, yet the lack of transparency in the pharmaceutical supply chain continues to present challenges. The average patient with diabetes still faces substantial annual medical expenses, a significant portion of which is tied to the management of their condition and the acquisition of supplies.

The current state of the insulin market illustrates the tension between medical innovation and market incentives. When a life-sustaining commodity is managed within a system where the patient has limited bargaining power and intermediaries profit from higher sticker prices, the result is a disconnect between value and cost. While the era of the $300 vial may be receding for many, the broader struggle for transparency and affordability in American medicine continues.

The legacy of the original insulin researchers—who sought to provide a gift to the world—now exists in stark contrast to a patchwork system that treats a century-old discovery as a high-margin product. The transition toward capped costs represents a significant shift, yet it highlights the irony of a 100-year-old discovery still being managed through a pricing model that reflects the complexities of a modern luxury good rather than a basic human necessity.